Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307701 | 0.83 | ALDH1A1 (0.40) | ALDH1A1KDM4ETSHRHTTTP53 | |
| Formic Acid SCHEMBL29105977 | 0.81 | MEN1 (0.38) | ALDH1A1KDM4ETSHRHTTTP53 | |
| Hydrochloric Acid SCHEMBL28613191 | 0.81 | ALDH1A1 (0.39) | ALDH1A1KDM4ETSHRHTTTP53 | |
| Trifluoroacetic Acid SCHEMBL28965161 | 0.78 | CHRM1 (0.36) | TSHRMAPTPOLB | |
| Trifluoroacetic Acid SCHEMBL28709650 | 0.77 | HSD17B10 (0.39) | ALDH1A1TSHR | |
| Trifluoroacetic Acid SCHEMBL30636582 | 0.75 | HSD17B10 (0.42) | ALDH1A1TSHRMAPTPOLB | |
| Trifluoroacetic Acid SCHEMBL5402957 | 0.75 | PKM (0.40) | ALDH1A1KDM4ETSHRTP53MAPT | |
| Trifluoroacetic Acid SCHEMBL295415 | 0.72 | TP53 (0.45) | ALDH1A1KDM4ETSHRHTTTP53 | |
| Trifluoroacetic Acid SCHEMBL6956793 | 0.71 | ALDH1A1 (0.50) | ALDH1A1KDM4ETSHRTP53MAPT | |
| Trifluoroacetic Acid SCHEMBL5901300 | 0.71 | ALDH1A1 (0.50) | ALDH1A1KDM4ETSHRTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310445-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | ANOVIA BIOSCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| CN-113354644-B | Pyrazolopyrimidine compound used as DPP-IV inhibitor and application thereof | 烟台药物研究所 | 2023-07-04 | — | — | CN | disclosed |
| CN-113354644-A | Pyrazolopyrimidine structure compound used as DPP-IV inhibitor and application thereof | 烟台药物研究所 | 2021-09-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310445-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | LOX, LOXL1, LOXL2 | ALDH1A1 487/4885KDM4E 828/4885TSHR 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.